CGRP and Migraine: The Peptide Drug Class Most Peptide-Curious People Have Never Heard Of

Calcitonin gene-related peptide is a 37-amino-acid neuropeptide that emerged from a 1980s splicing-variant discovery — alternate splicing of the calcitonin gene produces calcitonin in thyroid C cells and CGRP in neurons. Within the trigeminal nerve, CGRP is the most abundant neuropeptide; it's expressed in 35–50% of trigeminal ganglion neurons and is the most potent known peptidergic vasodilator of cerebral and dural blood vessels.

The migraine connection took two decades to nail down. CGRP serum levels are elevated during migraine attacks. Triptans, the workhorse acute migraine drug since the 1990s, reduce CGRP concentrations as headache pain resolves. Infusing CGRP into migraine sufferers reliably triggers attacks indistinguishable from spontaneous migraines. By the early 2010s the trigeminovascular hypothesis was firm: trigeminal nerve activation releases CGRP, CGRP drives vasodilation and neurogenic inflammation around dural and cerebral vessels, mast cell degranulation and pain transmission follow. Block CGRP, block migraine.

Between 2018 and 2023, the FDA approved eight drugs targeting that one peptide pathway. Half are monoclonal antibodies, with one targeting the CGRP receptor and three targeting the peptide itself. The other half are small-molecule receptor antagonists called gepants, available in oral and intranasal formulations. The pipeline that started with a single peptide discovery has turned into one of the most successful targeted therapy stories in modern neurology, and it's almost completely absent from the peptide-curious wellness conversation.

The injectable anti-CGRP biologics are the prevention workhorses. All four reduce monthly migraine days by roughly the same magnitude in pivotal trials, with subtle differences in mechanism and delivery.

The first to land was erenumab (Aimovig, Amgen/Novartis), approved in May 2018. It's the only one in the class that targets the CGRP receptor itself rather than the peptide. Monthly subcutaneous injection at 70 mg or 140 mg. In the pivotal STRIVE and ARISE trials, ~30% of patients achieved a 50%+ reduction in monthly migraine days at the higher dose.

Four months later, two anti-CGRP ligand antibodies arrived together. Fremanezumab (Ajovy, Teva) offered monthly or quarterly subcutaneous injection — the HALO and FOCUS trials showed ~34% of patients hitting the 50%+ MMD reduction threshold. Galcanezumab (Emgality, Eli Lilly) was a monthly subcutaneous, with EVOLVE-1 and EVOLVE-2 producing a 38% responder rate at 120 mg. A 2024 network meta-analysis tentatively favored fremanezumab on responder rate, though the differences across the four agents are small enough to be genotype- or pharmacology-noise rather than a clean clinical hierarchy.

Eptinezumab (Vyepti, Lundbeck) joined the class in February 2020, and it's the outlier on delivery — quarterly intravenous infusion rather than self-injection. PROMISE-1 and PROMISE-2 reported the highest responder rate of the class, with 49% of patients on 300 mg achieving 50%+ MMD reduction. The IV delivery is a real advantage for patients who can't manage subcutaneous self-injection, and a real disadvantage in terms of access — IV infusion means a clinic visit every three months.

The American Headache Society's 2024 consensus statement updated its first-line recommendation to include anti-CGRP biologics for episodic migraine with at least moderate disability. That's a meaningful shift — it puts a $890-per-month biologic into first-line territory rather than after multiple failed trials of older preventives like topiramate or propranolol. The economic argument depends on the AHS holding firm against insurer step-therapy push-back, which is an ongoing fight.

The gepants are small-molecule CGRP receptor antagonists — same target as the antibodies, fundamentally different drug class. They're orally bioavailable (or intranasally bioavailable in zavegepant's case), they have short half-lives suited to acute treatment, and they work both for stopping a migraine in progress and (for some) preventing the next one.

Ubrogepant (Ubrelvy, AbbVie) was the first oral gepant, approved in December 2019 for acute treatment only — 50 mg or 100 mg taken at migraine onset.

Rimegepant (Nurtec ODT, Pfizer) is the dual-indication standout, approved February 2020 for acute treatment and expanded to prevention in 2021. Orally disintegrating tablet, 75 mg, taken every other day for prevention or as needed for acute attacks. The dual indication means a patient on rimegepant for prevention can also use it to abort breakthrough attacks — a meaningful logistical advantage over carrying separate prevention and acute drugs.

For patients who want oral prevention without injections at all, atogepant (Qulipta, AbbVie) is the prevention-specific gepant — September 2021 approval, daily oral dosing at 10 mg, 30 mg, or 60 mg. The ADVANCE trial showed dose-dependent MMD reduction. Atogepant has become the go-to oral preventive for patients who would rather take a daily pill than do a monthly subcutaneous injection.

The most recent addition is zavegepant (Zavzpret, Pfizer), approved March 2023 as the first non-oral gepant. The intranasal route gets it working faster — onset around 15 minutes — which matters for migraines with severe nausea and vomiting where oral absorption is unreliable.

The key clinical distinction from triptans (the older acute migraine class) is mechanism. Triptans are 5-HT1B/1D agonists that work partly through cerebral vasoconstriction. That's the basis for both their migraine effect and their hard contraindication in stroke and ischemic heart disease patients. Gepants don't constrict blood vessels. They work upstream by blocking CGRP receptor signaling, which makes them safer in cardiovascular comorbidity and broadens the eligible patient population substantially.

The cost-effectiveness picture for gepants is more contested. A 2025 analysis concluded that ubrogepant, rimegepant, and zavegepant are not cost-effective vs older acute treatments for general migraine populations but are appropriate for patients experiencing two or fewer migraines per month — a population for whom the safety advantages over triptans matter most relative to the per-attack cost.

Galcanezumab is the only anti-CGRP biologic with FDA approval for episodic cluster headache — a separate indication granted in June 2019, less than a year after the migraine approval.

Cluster headache is a different beast. Severe, unilateral, periorbital pain in distinct clustering attacks — patients describe it as more intense than childbirth, often called 'suicide headache' for the despair the attacks produce. The pivotal galcanezumab trial in episodic cluster used a 300 mg monthly dose (higher than the 120 mg migraine dose) and showed a mean reduction of 8.7 weekly attacks vs 5.2 with placebo across weeks 1–3 — a difference of 3.5 attacks per week. 71% of treated patients hit a 50%+ reduction at week three, compared to 53% on placebo.

The trial enrollment was difficult enough that recruitment halted before reaching the planned 162-patient sample (final n=106). Cluster headache is an orphan-population indication, and even at high doses, the effect size is more modest than in migraine. The companion chronic-cluster trial actually missed its primary endpoint, and galcanezumab's cluster approval is therefore restricted to episodic, not chronic, cluster headache.

The practical takeaway for cluster patients: galcanezumab at 300 mg monthly is a real preventive option during cluster periods, with a stronger evidence base than verapamil or steroid bridges. The other CGRP biologics aren't approved for cluster, and the off-label use that does happen is at the discretion of the prescribing neurologist.

List price for the anti-CGRP biologics runs around $890 per month at retail. All four are comparably priced, and all four manufacturers run aggressive copay assistance programs that, for commercially insured patients, frequently bring out-of-pocket cost to $0–5 per month.

Aimovig's Bridge program supplies up to 12 doses free while insurance authorization is pursued; the post-approval $5 copay offer caps annual benefit at $3,500. Ajovy and Emgality offer $0 copay for commercially insured patients meeting eligibility. Vyepti's program reduces both drug and infusion-administration copays.

The gaps are real. Medicare and Medicaid patients are largely excluded from the manufacturer copay programs. Patients without commercial insurance face a hard cliff — list price for the antibodies, full retail for gepants, no clean discount pathway. The AHS first-line recommendation runs straight into the insurer-side reality that step therapy through topiramate, propranolol, or amitriptyline is still required by most plans before a CGRP biologic is approved.

For a patient with episodic migraine and commercial insurance, the practical sequence in 2026 looks like: trial of generic preventive (topiramate, propranolol, or amitriptyline) for 6–8 weeks; if inadequate response, prior authorization for an anti-CGRP biologic with manufacturer copay assistance; if biologic isn't tolerated or accessible, atogepant or rimegepant. The system is workable. It just isn't fast.

Generics are still some years off. Erenumab and the original biologics have biosimilar timelines that depend on Inflection Biosciences and other competitors, with first biosimilars likely 2028–2030 in the US. Atogepant and rimegepant patents extend further — no generic gepants are imminent. The class is going to remain expensive for the rest of the decade.

The CGRP class is the most successful peptide-pathway drug story in modern medicine, and yet it's almost entirely absent from peptide-curious wellness conversation. There are reasons for that — these are prescription drugs for a serious neurological condition, the patient population is heavily managed by specialist neurologists, and the wellness peptide community tends to focus on body composition, recovery, and longevity rather than chronic pain syndromes.

But the framework that produced these drugs is exactly the framework that informs the rest of peptide therapeutics. You identify a peptide implicated in a disease process, work out the pathway, develop targeted blockers, and prove it in RCTs. That's the same playbook behind the GLP-1 class, the orexin antagonists for insomnia, and the peptide-drug conjugates now reshaping oncology. CGRP just happens to be further along the maturity curve than most of those.

A few practical implications for people navigating peptide therapy from adjacent angles.

Migraine patients who've never tried an anti-CGRP biologic are almost certainly not on an optimized prevention regimen. The AHS recommendation now positions these as first-line options at moderate disability — a meaningful update worth raising with your clinician, particularly if your prevention history runs through topiramate or propranolol with mixed tolerability.

The gepant story matters most for triptan users with any cardiovascular concern. History of stroke or coronary disease, family risk, or just the age-related shift in baseline risk all push toward gepants as a safer acute alternative — they don't have the vasoconstrictive mechanism that makes triptans contraindicated in those populations.

Episodic cluster headache is the underrecognized indication. Galcanezumab 300 mg monthly is the only FDA-approved CGRP biologic for cluster, and the trial evidence is meaningful — worth asking your neurologist about, not least because most cluster bridges (verapamil, steroid courses, oxygen therapy) work but have substantial side effect or feasibility limits.

The broader lesson is that 'peptide-pathway drugs' aren't a niche category. They're the dominant mode of modern targeted therapy, and the migraine class is one of the cleanest examples of how a peptide discovery becomes a major therapeutic class. Worth knowing about, even if you came to peptides through a completely different door.